LUNAR IIIb Study Comparing Rosuvastatin and Atorvastatin in Subjects With Acute Coronary Syndromes
A 12-week Randomized, Open-label 3-arm, Parallel Group, Multicenter Phase IIIb Study Comparing Efficacy and Safety of Rosuvastatin 20mg and 40mg With That of Atorvastatin 80 mg in Subjects With Acute Coronary Syndromes
3 other identifiers
interventional
825
5 countries
56
Brief Summary
Comparison of rosuvastatin and atorvastatin in subjects with acute coronary syndromes
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Dec 2003
Typical duration for phase_3
56 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2003
CompletedFirst Submitted
Initial submission to the registry
September 21, 2005
CompletedFirst Posted
Study publicly available on registry
September 22, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2007
CompletedNovember 19, 2010
November 1, 2010
3.7 years
September 21, 2005
November 18, 2010
Conditions
Outcome Measures
Primary Outcomes (1)
Reduction of LDL-C following 12 weeks of treatment
Secondary Outcomes (1)
% change from baseline in LDL-C following 2 & 6 weeks of treatment; % change from baseline in TC, HDL-C, triglycerides, non-HDL-C, apolipoprotein A-1, apolipoprotein B, LDL-C/HDL-C, TC/HDL-C, non-HDL-C/HDL-C, ApoB/Apo A-1 @ weeks 6 & 12
Interventions
Eligibility Criteria
You may qualify if:
- Non-ST segment elevation ACS and ST segment elevation ACS who receive optimal reperfusion therapy
You may not qualify if:
- Previous Q-wave infarct within the last 4 weeks
- CK elevation not caused by myocardial injury
- uncontrolled hypertension at time of randomization
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (56)
Research Site
San Diego, California, United States
Research Site
Torrance, California, United States
Research Site
Bridgeport, Connecticut, United States
Research Site
Atlantis, Florida, United States
Research Site
Brandon, Florida, United States
Research Site
Jacksonville, Florida, United States
Research Site
Pensacola, Florida, United States
Research Site
Safety Harbor, Florida, United States
Research Site
Tampa, Florida, United States
Research Site
Aurora, Illinois, United States
Research Site
Chicago, Illinois, United States
Research Site
Lombard, Illinois, United States
Research Site
Melrose Park, Illinois, United States
Research Site
Peoria, Illinois, United States
Research Site
Anderson, Indiana, United States
Research Site
Indianapolis, Indiana, United States
Research Site
Des Moines, Iowa, United States
Research Site
Louisville, Kentucky, United States
Research Site
Owensboro, Kentucky, United States
Research Site
Covington, Louisiana, United States
Research Site
Shreveport, Louisiana, United States
Research Site
Annapolis, Maryland, United States
Research Site
Towson, Maryland, United States
Research Site
Ann Arbor, Michigan, United States
Research Site
Pontiac, Michigan, United States
Research Site
Troy, Michigan, United States
Research Site
Minneapolis, Minnesota, United States
Research Site
Saint Paul, Minnesota, United States
Research Site
Tupelo, Mississippi, United States
Research Site
Kansas City, Missouri, United States
Research Site
St Louis, Missouri, United States
Research Site
Kalispell, Montana, United States
Research Site
Newark, New Jersey, United States
Research Site
Albuquerque, New Mexico, United States
Research Site
Rochester, New York, United States
Research Site
Asheville, North Carolina, United States
Research Site
Cincinnati, Ohio, United States
Research Site
Fairview Park, Ohio, United States
Research Site
Springfield, Ohio, United States
Research Site
Oklahoma City, Oklahoma, United States
Research Site
Tulsa, Oklahoma, United States
Research Site
Bend, Oregon, United States
Research Site
Portland, Oregon, United States
Research Site
Danville, Pennsylvania, United States
Research Site
Memphis, Tennessee, United States
Research Site
Amarillo, Texas, United States
Research Site
Beaumont, Texas, United States
Research Site
Dallas, Texas, United States
Research Site
Lubbock, Texas, United States
Research Site
Chesapeake, Virginia, United States
Research Site
Burien, Washington, United States
Research Site
Wausau, Wisconsin, United States
Research Site
San José, Costa Rica
Research Site
San Salvador, El Salvador
Research Site
Ayer, Morocco
Research Site
Panama City, Panama
Related Publications (1)
Pitt B, Loscalzo J, Ycas J, Raichlen JS. Lipid levels after acute coronary syndromes. J Am Coll Cardiol. 2008 Apr 15;51(15):1440-5. doi: 10.1016/j.jacc.2007.11.075.
PMID: 18402897DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
AstraZeneca Crestor Medical Science Director, MD
AstraZeneca
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
September 21, 2005
First Posted
September 22, 2005
Study Start
December 1, 2003
Primary Completion
August 1, 2007
Study Completion
August 1, 2007
Last Updated
November 19, 2010
Record last verified: 2010-11